Social Outreach Research on new cancer treatment in the abdominal cavity Patients with peritoneal metastases, an advanced stage of cancer such as ovarian, stomach or colon cancer, often face a poor prognosis. Classic treatments with systemic chemotherapy have limited efficacy because the drug has difficulty reaching tumor cells on the peritoneum. In this study, a technique was studied in which the application of an electric field, which causes a mild electric current to pass through the peritoneal cavity, is used to achieve better penetration of the medication into the peritoneum. Traditional chemotherapy, usually administered through the blood, has difficulty penetrating the peritoneum. This is because the peritoneum acts as a protective barrier, preventing the absorption of drugs from the bloodstream. Intraperitoneal chemotherapy, in which drugs are administered directly into the peritoneal cavity, is seen as a promising alternative, but current methods are not yet effective enough. The technique examined in this study is Electromotive Drug Administration (EMDA). This involves applying a low electrical current with the aim of increasing drug penetration into the peritoneum. EMDA has already been used successfully in other medical fields, but not yet in the peritoneal cavity. During the study, which was conducted in a laboratory, nanoparticles - tiny particles to which medication can be linked – have been applied to healthy human peritoneal tissue. Following that, some tissue samples were subjected to EMDA, while other tissue samples were exposed to passive diffusion, a common method without the use of electricity. Comparing the results, it was found that under the influence of the electric current, the penetration of the nanoparticles into the tissue was significantly higher, especially in the deeper layers. These findings are promising, in fact, it suggests that EMDA could allow for more effective drug delivery into the peritoneal cavity and thus more effective treatment of peritoneal metastases. Although these findings are promising, it should be emphasized that further research is needed before the technique can be effectively applied in the clinic. In addition to further research in the laboratory, clinical trials will also need to be conducted to determine the effectiveness and safety of this technique in living human beings. What does this mean for patients? Should EMDA application prove effective in follow-up studies, it may significantly improve the treatment of patients with peritoneal metastases, offering them a chance for longer survival with a better quality of life. Social value and impact The social value of this research lies in the potential improvement of treatment options for patients with metastases on the peritoneum. For these patients, who often have poor prognosis, a more effective treatment may be found in EMDA by improving drug delivery (chemotherapeutics) to the peritoneum. In this way, a better local effect on the metastases could be obtained. A more efficient treatment of peritoneal metastases could improve not only the life expectancy but also the quality of life of patients. In addition, the application of EMDA in the abdominal cavity may offer opportunities for broader medical applications: due to its targeting mechanism of action, in principle, other medications, such as anti-inflammatories or antibiotics, could also be administered more effectively locally. This makes EMDA potentially suitable for various conditions in the abdominal cavity that could benefit from direct drug delivery, such as peritonitis or other forms of infections. In addition to the potential direct benefits to the patient, the research can contribute to technological innovation within medicine. Further development of the EMDA application in the abdominal cavity may reduce the gap between technology and medical practice. This research thus encourages the integration of new technologies into oncology and other medical fields, which can lead to breakthroughs and improvements in the quality of care.